Advertisement
Canada markets close in 2 hours 11 minutes

  • S&P/TSX

    22,044.10
    +172.14 (+0.79%)
     

  • S&P 500

    5,074.61
    +64.01 (+1.28%)
     

  • DOW

    38,553.68
    +313.70 (+0.82%)
     

  • CAD/USD

    0.7321
    +0.0020 (+0.27%)
     

  • CRUDE OIL

    83.16
    +1.26 (+1.54%)
     

  • Bitcoin CAD

    91,331.74
    +182.59 (+0.20%)
     

  • CMC Crypto 200

    1,435.62
    +20.86 (+1.47%)
     

  • GOLD FUTURES

    2,339.20
    -7.20 (-0.31%)
     

  • RUSSELL 2000

    2,004.97
    +37.50 (+1.91%)
     

  • 10-Yr Bond

    4.5900
    -0.0330 (-0.71%)
     

  • NASDAQ

    15,706.30
    +255.00 (+1.65%)
     

  • VOLATILITY

    16.04
    -0.90 (-5.31%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6834
    -0.0016 (-0.23%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND GAINS AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

Nigel Wray-backed Belluscura to raise £15 million for oxygen concentrator rollout

Graeme Evans
·1 min read
<p>The funds will be used for the roll out of its lightweight and portable oxygen concentrators </p> (Belluscura)

The funds will be used for the roll out of its lightweight and portable oxygen concentrators

(Belluscura)

A medical devices business backed by former Saracens rugby club chairman Nigel Wray is set to raise £15 million after revealing plans for a stock market listing.

Belluscura will use the funds for the roll out of its lightweight and portable oxygen concentrators that can replace cumbersome metal cylinders in treating lung diseases.

Its X-PLO2R device, which received approval from US regulators in March, is able to deliver up to 95% pure oxygen to patients 24 hours a day to help improve quality of life.

The London and Texas-based company will also look to progress other patents relating to oxygen enrichment devices and treatments.

ADVERTISEMENT

Belluscura is expected to be valued at between £50 million and £55 million on AIM following the placing of shares with institutions later this month. Wray holds a 17% stake.

SPARK Advisory Partners is acting as adviser, while Dowgate Capital is sole broker and bookrunner on the placing.

Read More

Love Hemp and Togetherall partner to give CBD fans free mental support

Boom time at Numis means big banker bonuses

Holiday Inn owner IHG sees US and China-fuelled bounce-back in demand